Marshall Wace LLP Invests $7.07 Million in Everus (NYSE:ECG)

Marshall Wace LLP bought a new stake in Everus (NYSE:ECG - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 107,501 shares of the company's stock, valued at approximately $7,068,000. Marshall Wace LLP owned 0.21% of Everus as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in ECG. SRS Capital Advisors Inc. bought a new stake in shares of Everus in the 4th quarter valued at approximately $26,000. Principal Securities Inc. bought a new stake in Everus in the fourth quarter valued at $27,000. HighMark Wealth Management LLC acquired a new position in Everus during the fourth quarter worth $28,000. Crews Bank & Trust bought a new position in shares of Everus during the fourth quarter valued at $29,000. Finally, Mendota Financial Group LLC acquired a new stake in shares of Everus in the 4th quarter valued at $36,000.

Insiders Place Their Bets

In other Everus news, CFO Maximillian J. Marcy bought 1,300 shares of the stock in a transaction on Tuesday, February 25th. The stock was purchased at an average price of $38.99 per share, with a total value of $50,687.00. Following the acquisition, the chief financial officer now owns 5,508 shares of the company's stock, valued at approximately $214,756.92. The trade was a 30.89 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Rocca Michael Della purchased 1,050 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was bought at an average cost of $47.56 per share, for a total transaction of $49,938.00. Following the purchase, the director now owns 2,027 shares in the company, valued at $96,404.12. This trade represents a 107.47 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders bought 3,750 shares of company stock valued at $153,853. 0.21% of the stock is currently owned by insiders.

Everus Stock Up 3.3 %

Shares of NYSE ECG opened at $36.93 on Wednesday. Everus has a 1-year low of $31.38 and a 1-year high of $77.93. The company has a quick ratio of 1.50, a current ratio of 1.58 and a debt-to-equity ratio of 0.47. The business has a 50-day moving average of $39.39.

Everus (NYSE:ECG - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The company reported $0.67 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.73 by ($0.06). As a group, sell-side analysts forecast that Everus will post 2.49 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Stifel Nicolaus reduced their price target on shares of Everus from $67.00 to $55.00 and set a "buy" rating on the stock in a research report on Wednesday, April 9th. Oppenheimer raised their price target on Everus from $70.00 to $80.00 and gave the company an "outperform" rating in a report on Tuesday, January 7th.

Everus Profile

Everus Construction Group is providing a full spectrum of construction services through its electrical and mechanical and transmission and distribution specialty contracting services principally in United States. Its specialty contracting services are provided to utility, transportation, commercial, industrial, institutional, renewable and other customers.

Want to see what other hedge funds are holding ECG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Everus (NYSE:ECG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.